<mods xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" ID="P0b002ee180384f3a">
<name type="corporate">
 <namePart>United States Government Publishing Office</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">publisher</roleTerm>
  <roleTerm authority="marcrelator" type="code">pbl</roleTerm>
</role>
 <role>
  <roleTerm authority="marcrelator" type="text">distributor</roleTerm>
  <roleTerm authority="marcrelator" type="code">dst</roleTerm>
</role>
</name>
<name type="corporate">
 <namePart>United States</namePart>
 <namePart>Government Accountability Office</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">author</roleTerm>
  <roleTerm authority="marcrelator" type="code">aut</roleTerm>
</role>
 <description>Government Organization</description>
</name>
<typeOfResource>text</typeOfResource>
<genre authority="marcgt">government publication</genre>
<language>
 <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<extension>
 <collectionCode>GAOREPORTS</collectionCode>
 <category>Legislative Agency Publications</category>
 <waisDatabaseName>gao_comptroller_general</waisDatabaseName>
 <branch>legislative</branch>
 <dateIngested>2010-08-12</dateIngested>
</extension>
<originInfo>
 <publisher>U.S. Government Printing Office</publisher>
 <dateIssued encoding="w3cdtf">2005-05-13</dateIssued>
 <issuance>monographic</issuance>
</originInfo>
<physicalDescription>
 <note type="source content type">deposited</note>
 <digitalOrigin>born digital</digitalOrigin>
 <extent>17 p.</extent>
</physicalDescription>
<classification authority="sudocs">GA 1.13:B-295888</classification>
<identifier type="uri">https://www.govinfo.gov/app/details/GAOREPORTS-B-295888</identifier>
<identifier type="local">P0b002ee180384f3a</identifier>
<identifier type="former package identifier">f:295888</identifier>
<recordInfo>
 <recordContentSource authority="marcorg">DGPO</recordContentSource>
 <recordCreationDate encoding="w3cdtf">2010-08-12</recordCreationDate>
 <recordChangeDate encoding="w3cdtf">2011-03-23</recordChangeDate>
 <recordIdentifier source="DGPO">GAOREPORTS-B-295888</recordIdentifier>
 <recordOrigin>machine generated</recordOrigin>
 <languageOfCataloging>
  <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</languageOfCataloging>
</recordInfo>
<accessCondition type="GPO scope determination">fdlp</accessCondition>
<extension>
 <docClass>COMPTROLLERDECISION</docClass>
 <accessId>GAOREPORTS-B-295888</accessId>
 <reportNumber>B-295888</reportNumber>
 <type>Comptroller General Decision</type>
 <law congress="105" isPrivate="false" number="65"></law>
 <law congress="108" isPrivate="false" number="375"></law>
 <statuteAtLarge volume="113">
                      <pages pages="677"></pages>
                </statuteAtLarge>
 <statuteAtLarge volume="118">
                      <pages pages="1811"></pages>
                </statuteAtLarge>
</extension>
<titleInfo>
 <title>Merck &amp; Company, Inc., B-295888, May 13, 2005</title>
</titleInfo>
<abstract>1.  Government Accountability Office has jurisdiction to review a protest
challenging the terms of a quotation request for a possible blanket
purchase agreement which is being used by the Department of Defense&apos;s
TRICARE Management Activity (pursuant to its statutory authority to
establish a pharmacy benefits program, including a uniform formulary) to
inform, and then implement, a TRICARE formulary determination. &lt;p/&gt;   2.  Decision by the TRICARE Management Activity to consider the cost of
pharmaceutical agents obtained by TRICARE beneficiaries at retail
pharmacies participating in TRICARE&apos;s retail pharmacy network as part of
its review of cost effectiveness undertaken to determine whether to add a
pharmaceutical agent to the uniform formulary is reasonable where the
statutory authorization for the pharmacy benefit program requires the
agency to consider the cost effectiveness of pharmaceutical agents as part
of any such determination, and where the record shows that more than half
of TRICARE&apos;s expenditures for pharmaceutical agents are incurred for
prescriptions filled by beneficiaries at such retail pharmacies.&lt;p/&gt;   3.  Protester&apos;s assertion that the agency is unreasonably obtaining
quotations applicable to only two of the venues where TRICARE
beneficiaries can have their prescriptions filled (military treatment
facilities and the mail order pharmacy), and is using what is, in essence,
a plug number unique to each company (i.e., the Federal Ceiling Price
applicable to certain types of purchases from the Federal Supply Schedule)
for its assessment of the costs that will be incurred in purchasing each
agent from participating retail pharmacies (the third venue where
prescriptions can be filled) is denied where the agency reasonably decided
that it should consider the costs of pharmaceutical agents obtained by
beneficiaries at such pharmacies; where the Secretary of the Department of
Veterans Affairs has determined that the Federal Ceiling Price applies to
TRICARE retail pharmacy purchases; and where the Federal Ceiling Price
will be the actual price paid by TRICARE if the Secretarial determination,
which is being challenged by certain pharmaceutical manufacturers, remains
in place.&lt;p/&gt;   4.  Protester&apos;s argument that a request for blanket purchase agreement
price quotations improperly fails to identify the relative importance of
clinical and cost effectiveness that will be used by the TRICARE Pharmacy
&amp; Therapeutics Committee to select pharmaceutical agents for inclusion on
the uniform and basic core formularies is denied where the request is
consistent with the statutory scheme, which does not identify the relative
importance of these two considerations, and which reserves for the
discretion of health care professionals the decision about which agents
will be included on the formulary, and where, even though this request is
limited to vendors submitting quotations for pharmaceutical agents
included on their Federal Supply Schedule contracts, there is no
requirement in the request that vendors select a particular configuration
of their offered products.</abstract>
<location>
 <url displayLabel="HTML rendition" access="raw object">https://www.govinfo.gov/content/pkg/GAOREPORTS-B-295888/html/GAOREPORTS-B-295888.htm</url>
 <url displayLabel="PDF rendition" access="raw object">https://www.govinfo.gov/content/pkg/GAOREPORTS-B-295888/pdf/GAOREPORTS-B-295888.pdf</url>
</location>
<identifier type="preferred citation">GAO/B-295888</identifier>
<location>
 <url displayLabel="Content Detail" access="object in context">https://www.govinfo.gov/app/details/GAOREPORTS-B-295888</url>
</location>
<note>Comptroller General Decision</note>
<extension>
 <searchTitle>GAO/B-295888; Merck &amp; Company, Inc., B-295888, May 13, 2005;
            </searchTitle>
</extension>
<relatedItem type="isReferencedBy">
 <titleInfo>
  <title>United States Statutes at Large</title>
  <partNumber>Volume 113 Page 677</partNumber>
</titleInfo>
 <identifier type="Statute citation">113 Stat. 677</identifier>
</relatedItem>
<relatedItem type="isReferencedBy">
 <titleInfo>
  <title>United States Statutes at Large</title>
  <partNumber>Volume 118 Page 1811</partNumber>
</titleInfo>
 <identifier type="Statute citation">118 Stat. 1811</identifier>
</relatedItem>
<relatedItem type="isReferencedBy">
 <titleInfo>
  <title>United States Public Law 65 (105th Congress)</title>
</titleInfo>
 <identifier type="public law citation">Public Law 105-65</identifier>
</relatedItem>
<relatedItem type="isReferencedBy">
 <titleInfo>
  <title>United States Public Law 375 (108th Congress)</title>
</titleInfo>
 <identifier type="public law citation">Public Law 108-375</identifier>
</relatedItem>
</mods>